Home
NSE: ZYDUSLIFE
Dividend Payout (Final)
₹ 3
Fiscal Year | Type Of Dividend | Dividend Payout (₹) | Record date | Ex Dividend Date |
---|
2023-24 | Final | 3 | 26-Jul-24 | 26-Jul-24 |
2022-23 | Final | 6 | 28-Jul-23 | 28-Jul-23 |
2021-22 | Final | 3 | 29-Jul-22 | 28-Jul-22 |
2020-21 | Final | 4 | - | 28-Jul-21 |
2019-20 | Interim | 4 | 24-Mar-20 | 23-Mar-20 |
Fiscal Year | Dividend Payout (₹) |
---|---|
2023-24 | 3 |
2022-23 | 6 |
2021-22 | 3 |
2020-21 | 4 |
2019-20 | 4 |
A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.
A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.
Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.
A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:
NSE: ZYDUSLIFE
Historical Market Cap of Zydus Lifesciences Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Market Cap
Historical Revenue, EBITDA and Net Profit of Zydus Lifesciences Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Revenue
EBITDA
Net Profit
Zydus Lifesciences Ltd rose for a third straight session today. The stock is quoting at Rs 984.6, up
Read more
03 Dec 2024 13:06
The issue pertains to the Input Tax Credit (ITC) carried forward through the TRAN-1 form. The compan
Read more
29 Nov 2024 12:04
Revenue from operations grew 19.87% year on year (YoY) to Rs 5,237 crore in the quarter ended 30 Sep
Read more
12 Nov 2024 15:22
Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2024
Read more
31 Oct 2024 11:58
ZyVac TCV is now eligible for purchase by United Nations (UN) agencies. It is indigenously developed
Read more
23 Oct 2024 14:50
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (
Read more
18 Oct 2024 09:29